The Centers for Medicare & Medicaid Services (CMS) issued the fiscal year (FY) 2024 Medicare Hospital Inpatient Prospective Payment System (IPPS) and Long‑Term Care Hospital (LTCH) Prospective Payment System (PPS) proposed rule. In addition to updating Medicare payment rates and policies for inpatient hospitals in FY 2024, the proposed rule aims to advance health equity and support underserved communities.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
The Centers for Medicare & Medicaid Services (CMS) released the 2024 Medicare Advantage and Part D Final Rule, which will revise regulations governing Medicare Advantage (MA), the Medicare Prescription Drug Benefit (Part D), Medicare cost plans, and Programs of All-Inclusive Care for the Elderly (PACE). The rule makes changes related to prior authorization, health equity, marketing and communications, and other areas on which Association for Clinical Oncology (ASCO) commented during the rulemaking process.
The Association for Clinical Oncology (ASCO) is urging lawmakers to prioritize reducing drug shortages, combatting tobacco use, and improving diversity in research as they review funding requests for fiscal year 2024.
On January 1, a provision of the Inflation Reduction Act (IRA) went into effect requiring drug companies to pay rebates to Medicare when prescription drug prices increase faster than the rate of inflation for certain drugs given to people enrolled in the program. The provision also provides for lower Medicare Part B beneficiary cost sharing on such drugs beginning April 1, 2023.
More than 30 patient and provider groups representing patients with serious health conditions, condemn Judge Kacsmaryk’s decision which threatens to restrict access to a Food and Drug Administration (FDA)-approved medication and other treatments. The organizations believe the ruling, in the case of Alliance for Hippocratic Medicine et al v FDA et al, sets a dangerous precedent that erodes an institution critical to Americans having access to the care they need.
Cisplatin has been in shortage since February 2023 (per FDA data), and the shortage has grown particularly acute in the last week or two. Accord/Intas released a cisplatin lot this week and subsequent releases are expected.
ASCO outlines the National Cancer Institute's National Cancer Plan and what it means for progress in cancer care, treatment, and access.
The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur:
On April 3, 2023, the Food and Drug Administration granted accelerated approval to enfortumab vedotin-ejfv (Padcev, Astellas Pharma) with pembrolizumab (Keytruda, Merck) for patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.
The Association for Clinical Oncology (ASCO) submitted a response to the House Energy and Commerce Committee’s Request for Information (RFI) on the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA). The legislation includes numerous programs, like the Strategic National Stockpile (SNS), that aid the U.S. in preparing for and responding to public health emergencies.
The Association for Clinical Oncology (ASCO) submitted a statement to the U.S. Senate Committee on Homeland Security and Government Affairs for a hearing titled, “Drug Shortage Health and National Security Risks: Underlying Causes and Needed Reforms.” ASCO’s statement highlighted the current drug shortages facing the oncology community and offered specific recommendations to help mitigate them.
On March 22, 2023, the Food and Drug Administration granted accelerated approval to retifanlimab-dlwr (Zynyz, Incyte Corporation) for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).
The Association for Clinical Oncology (ASCO) recently submitted a response to an RFI from the Senate HELP Committee, focusing on current oncology workforce demographics, drivers of oncology shortages across the care team, lack of workforce diversity, and the distribution of oncology professionals across rural America.
On March 16, 2023, the Food and Drug Administration approved dabrafenib (Tafinlar, Novartis) with trametinib (Mekinist, Novartis) for pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. The FDA also approved new oral formulations of both drugs suitable for patients who cannot swallow pills.
The Association for Clinical Oncology (ASCO) submitted comments in response to a Centers for Medicare & Medicaid Services' (CMS) proposal is to streamline prior authorization by requiring Medicare Advantage plans, Medicaid plans, and Qualified Health Plans (QHP) on Federally Facilitated Exchanges (FFEs) to establish an electronic prior authorization process that would be integrated into a provider’s workflow.
On March 7, Association for Clinical Oncology (ASCO) volunteers joined more than 85 representatives of One Voice Against Cancer (OVAC) on Capitol Hill for a lobby day in support of federal funding for medical research.